 Connection
David Becton to Antineoplastic Agents
This is a "connection" page, showing publications David Becton has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.306 |
|
|
|
-
Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
Score: 0.133
-
Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.
Score: 0.074
-
Stine KC, Wahl EC, Liu L, Skinner RA, Vanderschilden J, Bunn RC, Montgomery CO, Suva LJ, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Lumpkin CK. Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res. 2014 Mar; 32(3):464-70.
Score: 0.064
-
Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002 Mar 15; 20(6):1617-24.
Score: 0.028
-
Parham DM, Ready R, Stine K, Quiggins C, Becton D, North P. Comparison of manual and automated leukocyte counts for determination of the absolute neutrophil count: application to a pediatric oncology clinic. Med Pediatr Oncol. 2002 Mar; 38(3):183-6.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|